Is Equillium Inc (EQ) The Right Choice in Biotechnology?

Wednesday, August 12, 2020 11:46 AM | InvestorsObserver Analysts

A rating of 94 puts Equillium Inc (EQ) near the top of the Biotechnology industry according to InvestorsObserver. Equillium Inc's score of 94 means it scores higher than 94% of stocks in the industry. Equillium Inc also received an overall rating of 83, putting it above 83% of all stocks. Biotechnology is ranked 16 out of the 148 industries.

Overall Score - 83
EQ has an Overall Score of 83. Find out what this means to you and get the rest of the rankings on EQ!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 83 would rank higher than 83 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Equillium Inc Stock Today?

Equillium Inc (EQ) stock is lower by -11.41% while the S&P 500 has gained 1.27% as of 11:28 AM on Wednesday, Aug 12. EQ has fallen -$1.15 from the previous closing price of $10.11 on volume of 326,922 shares. Over the past year the S&P 500 has gained 15.37% while EQ has gained 138.30%. EQ lost -$1.58 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Close Update: Stocks Rally Friday Led by Technology to End Week Mixed

Wild Week Ends Up K Shaped

Sector Update: Biotech Stocks Lifting Health Care Sector to Big Advance

Stocks Shrug Off Early Weakness, Poised to Close Sharply Higher

Sector Update: Health Care

Is it Time to Dump Columbia Care Inc (CCHWF) Stock After it Is Down 4.62% in a Week?

Related Companies